GSK 4527363
Latest Information Update: 16 Jan 2025
Price :
$50 *
At a glance
- Originator GSK
- Class
- Mechanism of Action B cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Systemic lupus erythematosus
Most Recent Events
- 02 Sep 2024 Phase-I clinical trials in Systemic lupus erythematosus (In volunteers) in United Kingdom (unspecified route) (NCT06576271)
- 02 Sep 2024 GSK plans a phase I trial in United Kingdom (NCT06576271)
- 28 Aug 2024 Preclinical trials in Unspecified in United Kingdom (unspecified route) before August 2024